New TB prevention study for pregnant women with HIV shows promise
NCT ID NCT05122026
First seen Jan 10, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This study looks at whether a short course of TB prevention drugs (isoniazid and rifapentine) is safe for pregnant women with HIV. About 252 pregnant women will receive either a daily regimen for one month or a weekly regimen for three months. Researchers will also check how these drugs interact with their HIV medication (dolutegravir).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
FAMily Centre for Research with Ubuntu (FAMCRU)
Cape Town, Cape Town, 7505, South Africa
-
Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital
Klerksdorp, North West, 2571, South Africa
-
The Aurum Institute: Tembisa Clinical Research Centre
Tembisa, Gauteng, 1632, South Africa
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isoniazid and rifapentine
What this could lead to
If successful, this could provide a safe way to prevent tuberculosis in pregnant women with HIV without compromising their HIV treatment.
What could go wrong
This is an early-phase trial with only 252 participants, so results may not apply to all pregnant women. There are risks of side effects like liver problems or pregnancy complications.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.